Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Capricor Therapeutics (CAPR) Return on Sales (2016 - 2025)

Capricor Therapeutics has reported Return on Sales over the past 15 years, most recently at 8160.55% for Q4 2025.

  • Quarterly results put Return on Sales at 8160.55% for Q4 2025, down 815992.0% from a year ago — trailing twelve months through Dec 2025 was 8160.55% (down 815908.0% YoY), and the annual figure for FY2024 was 1.82%, down 93.0%.
  • Return on Sales for Q4 2025 was 8160.55% at Capricor Therapeutics, down from 7.34% in the prior quarter.
  • Over the last five years, Return on Sales for CAPR hit a ceiling of 0.07% in Q4 2023 and a floor of 8160.55% in Q4 2025.
  • Median Return on Sales over the past 5 years was 6.44% (2024), compared with a mean of 529.75%.
  • Biggest five-year swings in Return on Sales: skyrocketed 17012bps in 2021 and later plummeted -815992bps in 2025.
  • Capricor Therapeutics' Return on Sales stood at 85.26% in 2021, then soared by 91bps to 8.01% in 2022, then soared by 99bps to 0.07% in 2023, then crashed by -818bps to 0.63% in 2024, then crashed by -1295698bps to 8160.55% in 2025.
  • The last three reported values for Return on Sales were 8160.55% (Q4 2025), 7.34% (Q3 2025), and 5.2% (Q2 2025) per Business Quant data.